The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

UNAIDS Executive Director Winnie Byanyima speaks during the Launch of HIV Prevention Project in Johannesburg, South Africa, ...

New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...

To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of USAID funding ...

The Relist Watch column examines cert petitions that the Supreme Court has “relisted” for its upcoming conference. A short explanation of relists is available here. The Supreme Court continues to ...